Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap Up – Time to Buy?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) gapped up before the market opened on Thursday . The stock had previously closed at $9.11, but opened at $9.68. Lexeo Therapeutics shares last traded at $9.4970, with a volume of 192,264 shares.

Analyst Upgrades and Downgrades

Several analysts have weighed in on LXEO shares. Cantor Fitzgerald assumed coverage on Lexeo Therapeutics in a research note on Monday, December 1st. They set an “overweight” rating and a $19.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research report on Thursday, December 11th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Raymond James Financial initiated coverage on shares of Lexeo Therapeutics in a report on Wednesday. They issued a “strong-buy” rating and a $25.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Lexeo Therapeutics Trading Up 3.9%

The company’s 50-day moving average price is $9.25 and its two-hundred day moving average price is $6.39. The company has a market cap of $755.45 million, a P/E ratio of -3.83 and a beta of 1.76.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.15. Equities analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Insider Transactions at Lexeo Therapeutics

In other news, insider Eric Adler sold 3,382 shares of the company’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $30,235.08. Following the completion of the sale, the insider directly owned 73,261 shares of the company’s stock, valued at $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Richard Nolan Townsend sold 13,133 shares of Lexeo Therapeutics stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $8.94, for a total value of $117,409.02. Following the completion of the transaction, the chief executive officer directly owned 242,118 shares in the company, valued at $2,164,534.92. This represents a 5.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 24,646 shares of company stock valued at $221,037 over the last three months. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Large investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC grew its position in Lexeo Therapeutics by 10.6% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 16,595 shares of the company’s stock worth $110,000 after purchasing an additional 1,595 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Lexeo Therapeutics by 6.1% during the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after buying an additional 1,626 shares in the last quarter. Intech Investment Management LLC raised its position in Lexeo Therapeutics by 20.7% during the second quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after buying an additional 2,342 shares during the period. AXQ Capital LP lifted its stake in Lexeo Therapeutics by 19.6% in the 3rd quarter. AXQ Capital LP now owns 14,921 shares of the company’s stock worth $99,000 after acquiring an additional 2,446 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Lexeo Therapeutics by 42.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the company’s stock worth $63,000 after acquiring an additional 2,799 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.